Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | HTR7 | P34969 | 5/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | QPCT | Q16769 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4794001 | 0.93 | POLB (0.55) | POLBALOX15TSHRSMN1; SMN2PPARG | |
| SCHEMBL5333783 | 0.90 | POLB (0.46) | POLBALOX15TSHRSMN1; SMN2PPARG | |
| SCHEMBL4792873 | 0.88 | POLB (0.47) | POLBALOX15TSHRSMN1; SMN2PPARG | |
| SCHEMBL4793268 | 0.86 | POLB (0.49) | POLBALOX15TSHRSMN1; SMN2PPARG | |
| SCHEMBL4795533 | 0.85 | ALDH1A1 (0.40) | POLBTSHRHTR7HTR6ALDH1A1 | |
| SCHEMBL4793998 | 0.84 | POLB (0.50) | POLBALOX15TSHRSMN1; SMN2PPARG | |
| SCHEMBL6784033 | 0.82 | HTR7 (0.46) | POLBALOX15TSHRSMN1; SMN2PPARG | |
| SCHEMBL5333778 | 0.82 | POLB (0.46) | POLBALOX15TSHRSMN1; SMN2PPARG | |
| SCHEMBL4793833 | 0.82 | TLR7 (0.38) | SMN1; SMN2 | |
| SCHEMBL4793736 | 0.80 | TLR7 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513524-A4 | ETHER SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES CO (US) | 2008-09-03 | — | — | EP | disclosed |
| US-7220758-B2 | Ether substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-20060252792-A1 | ETHER SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2006-11-09 | — | — | US | disclosed |
| US-7125890-B2 | Ether substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1513524-A2 | ETHER SUBSTITUTED IMIDAZOPYRIDINES | 3M Innovative Properties Company (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20050032830-A1 | Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors | 3M INNOVATIVE PROPERTIES COMPANY | 2005-02-10 | — | — | US | disclosed |
| US-6797718-B2 | Ether substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-28 | — | — | US | disclosed |
| US-20040010007-A1 | Ether substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-15 | — | — | US | disclosed |
| WO-2003103584-A2 | ETHER SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252792-A1 | ETHER SUBSTITUTED IMIDAZOPYRIDINES | IL2, IL4, MYD88 | POLB 3686/4885ALOX15 2786/4885TSHR 893/4885 |
| US-20050032830-A1 | Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors | IL2, IFNG, TSLP | POLB 3743/4885ALOX15 750/4885TSHR 938/4885 |
| US-20040010007-A1 | Ether substituted imidazopyridines | IL2, IL4, MYD88 | POLB 3686/4885ALOX15 2786/4885TSHR 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.